Horizon Discovery Predesigned Synthetic sgRNAs
Horizon Discovery is now offering predesigned synthetic single guide RNA (sgRNA). The sgRNAs are available individually or as library collections, and are being offered as an expansion to the company's Edit-R gene engineering platform. Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts, even in complex, difficult-to-edit cell types and experimental models, Horizon said. The synthetic sgRNAs have been designed to maximize the likelihood of functionally knocking out the gene or genes of interest while minimizing off-target effects.
When paired with Cas9 mRNA or Cas9 protein, the sgRNAs also allow researchers to perform DNA-free gene editing in a new one-part format, streamlining their gene editing workflows without the potential for nuclease or guide integration into the cell's genome. They can also be paired with expressed formats such as Cas9 integrated cell lines.
Fluxion Biosciences Spotlight Liquid Biopsy NGS Panels
Fluxion Biosciences has launched three new targeted next-generation sequencing liquid biopsy panels, including Spotlight Myeloid, Spotlight EGFR, and the Spotlight TP53. The Alameda, California-based firm's Spotlight Myeloid panel includes 478 amplicons that cover 23 clinically relevant genes implicated in acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms. The Spotlight EGFR panel offers contiguous coverage of EGFR and hotspot coverage of BRAF, KRAS, and NRAS mutations, using a 17-amplicon design to generate multiplex libraries compatible with Illumina sequencing platforms. The Spotlight TP53 panel uses 21 amplicons with an average size of 140 base pairs, providing coverage of all TP53 coding regions. According to Flux Bio, the panels have been validated and come with its ERASE-Seq variant caller.
Caris Life Sciences MI GPS Score
Caris Life Sciences has launched the MI GPS (Genomic Profiling Similarity) Score, an AI-driven tumor type biology similarity score that uses more than 6,500 mathematical models in the machine learning algorithm to compare molecular characteristics of a patient's tumor against Caris' extensive database. The results are intended to provide new insights into the molecular subtype of cancer of unknown primary (CUP) cases, atypical clinical presentation cases, and other difficult-to-treat cancer cases to help guide treatment decisions, the company said.
For more new products and services, please visit the New Products page on our website.